# Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

> **NCT03872661** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 36 (estimated)

## Conditions studied

- Lung Cancer Stage III

## Interventions

- **DRUG:** IBI308
- **DRUG:** Bevacizumab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **PROCEDURE:** Thoracic surgery

## Key facts

- **NCT ID:** NCT03872661
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-03-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03872661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03872661, "Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03872661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*